Clinical Trials Logo

Filter by:
NCT ID: NCT05812430 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer

Start date: April 10, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of anlotinib plus TQB2450 combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer

NCT ID: NCT05812248 Recruiting - Noncardiac Surgery Clinical Trials

Prediction of Vascular Events After Major Non-Cardiac Surgery : an Observational Prospective Cohort Study

PREVENGE-CB-2
Start date: July 1, 2022
Phase:
Study type: Observational [Patient Registry]

This observational study includes patients at medium-to-high cardiovascular risks undergoing major noncardiac surgery, measures their baseline demographic and clinical characteristics, preoperative cardiac biomarkers and intraoperative surgery/anesthesia related data, and screens them for the occurrence of myocardial injury and major adverse cardiac events after surgery. The primary aim is to develop and validate a pre- and an immediate postoperative prediction model for occurrence of major adverse cardiac events.

NCT ID: NCT05812040 Recruiting - Breast Neoplasms Clinical Trials

Clinical Value of Breast High-Resolution MR Ductography in Patients With Pathological Nipple Discharge

Start date: March 2, 2023
Phase: N/A
Study type: Interventional

Nipple discharge is one of the common symptoms of breast disease patients. Nipple discharge can be divided into physiological and pathological nipple discharge (PND). Among patients with PND symptoms who undergo biopsy, 5%-21% of them are malignant, and the risk of malignancy increases with age. The primary diagnostic imaging methods for PND patients include mammography and breast ultrasound. Nearly half of PND patients who undergo traditional mammography and ultrasound examination have negative findings, but this does not rule out the presence of malignant lesions. Central duct excision is the gold standard for PND diagnosis, but invasive surgery without imaging guidance can lead to some complications. Magnetic Resonance Ductography (MRD), which uses water imaging technology to visualize the inside of the duct without contrast injection, can show imaging features of ductal lesions such as filling defects, irregularities of duct walls, and ductal obstruction. However, previous studies have shown that the signal-to-noise ratio of MRD images needs to be improved. Microscopy coil has the characteristics of small voxels and high spatial resolution, making it suitable for high signal-to-noise ratio imaging of small superficial structures. This provides a hardware foundation for improving the quality of MRD images. Therefore, in this study, the investigators aim to use the 3T MR instrument and microscopy coil to perform non-invasive high-resolution Magnetic Resonance Ductography (HR-MRD) on PND patients to evaluate the ability of HR-MRD to detect PND causes and the imaging features of duct-related lesions on HR-MRD, to assist in the accurate diagnosis and treatment of PND.

NCT ID: NCT05811975 Recruiting - Clinical trials for Refractory Solid Tumors

KSX01-TCRT Injection Project in Solid Tumors

Start date: March 7, 2023
Phase: Early Phase 1
Study type: Interventional

1) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.

NCT ID: NCT05811676 Recruiting - Placenta Previa Clinical Trials

Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Pregnant Women With Placenta Previa

TRAPP
Start date: July 12, 2023
Phase: Phase 3
Study type: Interventional

Many RCT(randomized controlled trial) studies reported that tranexamic acid reduced blood loss in women who had elective cesareans. However, most of these elective cesareans are without high-risk factors of postpartum hemorrhage, such as placenta previa. The prophylactic use of tranexamic acid in the placenta previa is not clear. studies had poor quality and lacked adequate power to assess severe adverse events.

NCT ID: NCT05811598 Recruiting - Myopia Clinical Trials

Real Word Study on Myopia Control With Repeated Red Light Therapy for Ages of 3~6 Years Old

RMC
Start date: March 21, 2023
Phase: N/A
Study type: Interventional

Repeated Red Light Therapy had been used as an amblyopia therapy for children as well as the myopia control in primary schools. However, ultra low lever of red light therapy with irradiance of 0.37mW and 0.60mW effectiveness and safety for 3~ 6 year-old myopia treatment or slow myopia progression are seldom reported.

NCT ID: NCT05811481 Recruiting - Clinical trials for Hepatocellular Carcinoma

Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy

ROSE
Start date: December 27, 2022
Phase:
Study type: Observational [Patient Registry]

. 1 Clarify the difference in efficacy of regofinib combined with TACE compared with second-line treatment of advanced liver cancer; 2. To evaluate the safety and prognostic imaging factors of regorofenib in advanced second-line therapy; 3, to explore whether it is necessary to increase the treatment of TACE in the second-line treatment of advanced HCC.

NCT ID: NCT05811442 Recruiting - Alzheimer's Disease Clinical Trials

Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease

Start date: April 18, 2023
Phase: Phase 2
Study type: Interventional

This is a multi-center, Phase IIa, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety of two doses of 50561 compared to placebo in participants diagnosed with mild to moderate Alzheimer's disease.

NCT ID: NCT05810961 Recruiting - Clinical trials for Membranous Nephropathy

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Primary Membranous Nephropathy (ZL-1103-014)

Start date: February 20, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of efgartigimod IV in Chinese patients with primary membranous nephropathy (pMN).

NCT ID: NCT05810948 Recruiting - Lupus Nephritis Clinical Trials

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)

Start date: February 21, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of efgartigimod IV in Chinese patients with active lupus nephritis (LN)